Literature DB >> 9002070

Comparison of three different hybridization assays in the quantitative measurement of serum hepatitis B virus DNA.

S J Hwang1, S D Lee, R H Lu, C Y Chan, L Lai, R L Co, M J Tong.   

Abstract

The measurement of hepatitis B virus (HBV) DNA, is important for monitoring and evaluating the efficacy of anti-viral agents in the treatment of patients with chronic hepatitis B. Three different hybridization assays for quantitative measurement of HBV DNA: direct membrane (dot-blot) hybridization, liquid hybridization (Abbott HBV DNA assay) and branched DNA signal amplification assay (Quantiplex, Chiron), were applied to 114 serial serum samples obtained from 13 patients with chronic active hepatitis B who had received ribavirin 600 mg daily for four weeks. Among the three assays, the correlation was found to be highest between Quantiplex and Abbott HBV DNA assay (r = 0.71, p < 0.01), moderate between Quantiplex and dot-blot hybridization (r = 0.58, p < 0.01) and lowest between dot-blot hybridization and Abbott HBV DNA assay (r = 0.27, p < 0.01). Quantiplex detected 107 (94%) of 114 specimens and was the most sensitive assay. All specimens positive by dot-blot hybridization and Abbott HBV DNA assays were detected positive by Quantiplex. The Dot-blot hybridization assay detected all 89 (100%) specimens with a high HBV DNA level (> or = 10 million genome equivalent (Meq)/ml by Quantiplex), but detected only 7 (50%) of 14 specimens with a low HBV DNA level (< 10 Meq/ml). The Abbott HBV DNA assay detected 85 (95%) of 89 specimens with a high HBV DNA level, but detected only 3 (17%) of 18 specimens with a low HBV DNA level. Among 7 negative specimens in the Quantiplex assay, 2 were detected positive by polymerase chain reaction. In conclusion, Quantiplex assay was more sensitive than Abbott HBV DNA assay and dot-blot hybridization assay for quantitative measurement of serum HBV DNA and can be used in the evaluation of the therapeutic drug effect on chronic hepatitis B patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9002070     DOI: 10.1016/s0166-0934(96)02093-9

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA.

Authors:  S J Hwang; R H Lu; M L Wood; Y J Wang; F Y Chang; S D Lee
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels.

Authors:  Vincent A Lopez; Eric J Bourne; Michael W Lutz; Lynn D Condreay
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

Authors:  S G Lim; C T Wai; A Rajnakova; T Kajiji; R Guan
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

4.  Sensitive and Specific Detection of Mycoplasma species by Consensus Polymerase Chain Reaction and Dot Blot Hybridization.

Authors:  Sunhwa Hong; Hyun-A Lee; Sang-Ho Park; Okjin Kim
Journal:  Lab Anim Res       Date:  2011-06-22

5.  Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Authors:  Jung Min Ha; Won Sohn; Ju Yeon Cho; Jeung Hui Pyo; Kyu Choi; Dong Hyun Sinn; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Chul Koh; Seung Woon Paik; Byung Chul Yoo; Yong-Han Paik
Journal:  Clin Mol Hepatol       Date:  2015-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.